Skip to main content
Premium Trial:

Request an Annual Quote

Others Out There Already

Sanofi is no longer pursing the development of an mRNA-based vaccine for SARS-CoV-2, Reuters reports.

This move, the Wall Street Journal adds, comes despite promising results from an early-stage clinical trial of its SARS-CoV-2 vaccine. The trial showed that the candidate vaccine elicited neutralizing antibodies, the Journal notes. However, it adds that Thomas Triomphe, head of Sanofi's vaccine business says SARS-CoV-2 vaccine field is crowded and well served by existing vaccines.

"Would it, responsibly, be the best use of this wealth of science afforded by mRNA vaccines to make a COVID-19 vaccine and try and bring another mRNA COVID-19 vaccine to people who already today may not want an mRNA COVID-19 vaccine? Clearly not," Triomphe says, according to Reuters.

Instead, the Journal reports that Sanofi will be shifting its mRNA vaccine research to focus on other infectious diseases and already has an mRNA-based vaccine for flu in early-stage clinical trials.

At the same time, Reuters notes that Sanofi is still developing a traditional protein-based SARS-CoV-2 vaccine in collaboration with GlaxoSmithKline, which the companies reported in May had had encouraging early results.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.